An estimated one-quarter of adults in the U.S. have nonalcoholic fatty liver disease (NAFLD), an excess of fat in liver cells that can cause chronic inflammation and liver damage, increasing the risk of liver cancer. Now, UT Southwestern researchers have developed a simple blood test to predict which NAFLD patients are most likely to develop liver cancer.
The origins of our blood may not be quite what we thought. Using cellular “barcoding” in mice, a groundbreaking study finds that blood cells originate not from one type of mother cell, but two, with potential implications for blood cancers, bone marrow transplant, and immunology. Fernando Camargo, PhD, of the Stem Cell Program at Boston Children’s Hospital led the study, published in Nature on June 15.
Mount Sinai researchers have for the first time identified genes that predict a good response to a vital new therapy for a blood cancer that can have serious side effects for some patients.
Here are some of the latest articles that have been added to the Aging channel on Newswise, a free source for journalists.
A study from Karolinska Institutet in Sweden sheds new light on the question of whether the sex and previous pregnancy of blood donors affects survival in patients who receive red blood cell transfusions.
A new study by researchers at Washington University School of Medicine in St. Louis shows that treatment with an immunity boosting protein called interleukin 7 (IL-7) after an infusion of genetically modified T cells causes the cancer-fighting CAR-T cells to grow in number and become more effective at killing tumor cells.
An investigational drug taken while undergoing chemotherapy demonstrated superior overall survival compared to chemotherapy alone in adult patients with a common, highly aggressive subtype of acute myeloid leukemia (AML).
A new research describes how highly proliferative leukemia cells end up becoming normal cells that no longer multiply, by changing the chemical modifications -the so-called epigenetics- of a type of its genetic material: the messenger RNA.
Momelotinib, an oral pill taken once a day, significantly improved outcomes of patients treated for myelofibrosis (MF), a rare but fatal bone marrow cancer, researchers reported June 7. Ruben Mesa, MD, FACP, executive director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, presented results of the MOMENTUM phase 3 randomized study, which evaluated momelotinib against a second medication, danazol, in symptomatic and anemic MF patients previously treated with standard-of-care JAK inhibitor therapy.
On Tuesday, June 7, Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, will present the long-term results of a phase 2 clinical trial combining crenolanib, a second-generation FLT3 inhibitor, with standard intensive chemotherapy for treatment of adults with newly diagnosed FLT3-mutant acute myeloid leukemia (AML), in a talk at the American Society of Clinical Oncology (ASCO) annual meeting 2022.
A mysterious form of diabetes known as malnutrition-related diabetes afflicts tens of millions of people in Asian and sub-Saharan African countries. Its victims—mainly thin and impoverished adolescents and young adults—rarely live more than a year after diagnosis. Their young age and thinness suggest type 1 diabetes (T1D), but insulin injections usually don’t help and can even cause death from low blood sugar. Nor do patients seem to have type 2 diabetes (T2D), which is typically associated with obesity.
Instructors from the American College of Surgeons STOP THE BLEED® program are available for media interviews as the nation observes National STOP THE BLEED® Month in May.
Emergency Medicine and Trauma Surgery researchers at Vanderbilt University Medical Center (VUMC) are joining Vanderbilt LifeFlight in a Department of Defense (DOD)-funded clinical trial aimed at improving survival with resuscitation techniques used to keep patients alive after a traumatic injury.
A $2.3 million National Institutes of Health (NIH) grant will fund Jianjun Guan and Fuzhong Zhang’s effort to develop and deliver therapeutic proteins to help treat injured limbs.
An international team led by a University of Toronto researcher has found that an antibody detectable in blood predicts severe Crohn’s disease and is detectable up to seven years prior to disease diagnosis.
The American College of Surgeons (ACS) applauds Senators Menendez and Boozman and Representatives O’Halleran and Wenstrup for introducing the Prevent Blood Loss with Emergency Equipment Devices Act (Prevent BLEEDing Act). This legislation is crucial to support efforts to bring STOP THE BLEED® training and equipment directly to all U.S. citizens.
.jpg&width=300&height=300)
2011 changes in policies and recommendations related to the use of erythropoietin-stimulating agents were associated with lower hemoglobin levels and lower risks of major adverse cardiovascular events, mortality, and stroke among adults receiving hemodialysis, but with a higher risk of heart attack.
A test for the common blood cancer multiple myeloma also holds clear clues that the patient has one of the most uncommon and deadly forms of this cancer, investigators say.
A commonly used blood pressure medication may help improve measures of frailty in prefrail older adults, according to a new study by researchers with UTHealth Houston. The study was published in The Journals of Gerontology.
Adolescent and young adult survivors of acute lymphoblastic leukemia and acute myeloid leukemia, two of the most common leukemias for ages 15 to 39 years old, have increased risk of mortality than the general population for decades after initial diagnosis. Researchers investigated disparities specific to survivorship to learn about patients’ outcomes after they survived their initial diagnosis; and analyzed data from cancer survivors who were at least five years post treatment. Results suggest there is a gap in critical data surveillance that needs to be examined to further understand what is impacting long-term survivorship for AYAs.
Ten years ago, Tom and Kari Whitehead came to Children’s Hospital of Philadelphia (CHOP) looking for a miracle. Their 6-year-old daughter, Emily, had relapsed in her battle with acute lymphoblastic leukemia (ALL), after many months of unsuccessful chemotherapy and a disease that had progressed so rapidly that she was ineligible for a bone marrow transplant to treat it. Her family came to CHOP in the hopes that Dr. Stephan Grupp, a pioneer in the field of cellular immunotherapy, could provide the miracle they were looking for.
妙佑医疗国际(Mayo Clinic) 个体化医学中心（Center for individualized Medicine ）的新研究发现，携带ASXL1突变体的慢性粒单核细胞白血病（一种罕见骨髓癌）患者中存在独特的表观遗传变化，可激活有害基因并导致癌细胞更快生长。ASXL1基因突变还能使疾病转化为更具侵袭性的急性髓细胞性白血病。
Uma nova pesquisa do Centro de Medicina Individualizada da Mayo Clinic descobre que pacientes com leucemia mielomonocítica crônica com mutação ASXL1 (um tipo incomum de câncer de medula óssea) têm alterações epigenéticas específicas que podem ativar genes nocivos e fazer com que o câncer cresça mais rapidamente.
وجد بحث جديد من مركز مايو كلينك للطب الفردي أن المرضى المصابين بابيضاض الدم المايلومونيكي المزمن بسبب طفرة ASXL1 - وهو نوع غير شائع من سرطان نخاع العظم - لديهم تغييرات لاجينية مميزة يمكنها تنشيط الجينات الضارة وتتسبب في نمو السرطان بشكل أسرع. كما يمكن لطفرة ASXL1 الجينية تحويل المرض إلى ابيضاض الدم النقوي الحاد الأكثر عدوانية.
Las nuevas investigaciones del Centro para Medicina Personalizada de Mayo Clinic descubren que los pacientes con leucemia mielomonocítica crónica con mutación en el gen ASXL1, un tipo raro de cáncer de la médula ósea, sufren cambios epigenéticos distintivos que activan genes nocivos y hacen que el cáncer se desarrolle con más rapidez.
In Physics of Fluids, researchers present clinicians with information about the risk factors for atherosclerotic plaque formation from a mechanical point of view. The scientists are exploring whether it is possible to screen and intervene early for people at risk for atherosclerotic disease from the perspective of hemodynamics, using color Doppler ultrasound, coronary computed tomography angiography, and other screenings. The researchers used a multipoint, noncontact laser flow measurement method called microparticle image velocimetry.
Acute myeloid leukaemia is a rare and devastating blood cancer that is highly resistant to treatment. Now, Australian scientists have discovered a way to suppress a specific protein that promotes drug resistance.
Tufts engineers create a glowing sensor made from a silk gel that can be implanted under the skin to detect blood oxygen levels in real time. The sensor provides proof of concept for detecting other blood components, such as glucose
Cardiologists from the Structural and Congenital Heart Center and Cardiac Surgeons at Hackensack Meridian Hackensack University Medical Center/Hackensack Meridian School of Medicine have reported what is believed to be the very first patient with heart failure and a blood clot to undergo a minimally invasive transcatheter aortic valve replacement using CT (computed tomography) fusion imaging, a technique that employs two different imaging modalities.
In the ultimate use of telemedicine, Stephan Moll, MD, worked with NASA to treat a U.S. astronaut’s blood clot during a mission on the International Space Station. That led to a study on how blood flows in zero gravity, and if astronauts are at greater risk of developing blood clots in space.
A stroke and subsequent brain injury qualified 65-year-old Linda Carmichael for a national, randomized clinical trial led locally by Sunil A. Sheth, MD, with McGovern Medical School at UTHealth Houston, investigating the safety and efficacy of endovascular thrombectomy plus medical management compared to medical management alone in certain LVO stroke patients.
Tranexamic acid (TXA) – a medication given to reduce the risk of bleeding during some orthopaedic surgical procedures – can be safely used in patients with intertrochanteric (IT) hip fractures who are at high risk of blood clot-related complications, reports a study in The Journal of Bone & Joint Surgery. The journal is published in the Lippincott portfolio in partnership with Wolters Kluwer.
May 19 will observe the fifth annual National STOP THE BLEED® Day, which falls during the broader observance of National STOP THE BLEED® Month in May.
A Johns Hopkins Children’s Center-led national quality improvement collaborative highlights a “less is more” method that may prevent antibiotic overprescribing
CAR-T therapy, a form of immunotherapy that revs up T-cells to recognize and destroy cancer cells, has revolutionized the treatment of blood cancers, including certain leukemias, lymphomas, and most recently, multiple myeloma. However, Black and Hispanic people were largely absent from the major clinical trials that led to the U.S. Food and Drug Administration approval of CAR-T cell therapies.
New research from NUI Galway and Boston University has identified a blood biomarker that could help identify people with the earliest signs of dementia, even before the onset of symptoms.
oswell Park Comprehensive Cancer Center specialists will share the latest advances and developments in the treatment of blood-related cancers at the 2022 Tandem Transplantation & Cellular Therapy Meetings of American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR) in Salt Lake City, Utah, from April 23 to 26.
Rutgers Cancer Institute of New Jersey and RWJBarnabas Health have appointed Ira Braunschweig, MD, as chief, Section of Transplant and Cell Therapy at Rutgers Cancer Institute, chief of the Transplant and Cell Therapy Service of the RWJBarnabas Health Oncology Service Line, and director for Cell Therapy and Bone Marrow Transplantation at Robert Wood Johnson University Hospital, an RWJBarnabas facility.
Drug may safely boost platelet levels in patients with immune thrombocytopenia.
Actors from two popular medical TV dramas have joined efforts with the American College of Surgeons (ACS) to spread lifesaving STOP THE BLEED® information to the people of Ukraine through a new Public Service Announcement (PSA) released today.
去年早些时候，Veronica Ciudad-Real被诊断出患有多发性骨髓瘤，一种她从未听说过的血癌，这让她感到非常惊讶和困惑。她才40岁，比该疾病的大多数患者都要年轻。随后她又了解到，在她的祖国萨尔瓦多无法获得她所需的治疗。
عندما تم تشخيص فيرونيكا سيوداد ريال في أوائل العام الماضي بالورم النقوي المتعدد، وهو سرطان دم لم تسمع به من قبل، كان لديها أسئلة بلا إجابات. لقد كانت في الأربعين من عمرها، أي أصغر من معظم المصابين بالمرض.
Quando Veronica Ciudad-Real foi diagnosticada no começo do ano passado com mieloma múltiplo, um câncer do sangue do qual ela nunca tinha ouvido falar, ela teve mais perguntas do que respostas. Aos 40 anos, ela era mais jovem do que a maioria das pessoas com essa doença.
Cuando Verónica Ciudad-Real recibió a principios del año el diagnóstico de mieloma múltiple, cáncer de la sangre del cual ella nunca había escuchado hablar, tuvo muchas preguntas y pocas respuestas. A sus 40 años, era más joven que la mayoría de las personas que sufren de esta enfermedad.
Preventing the formation of a sticky, web-like substance that can form in blood vessels after a stroke could protect the brain and lead to better outcomes for patients, studies in mice suggest. The research was reported in the Journal of Clinical Investigation and led by scientists at University of Utah Health.
SEATTLE — April 6, 2022 — Below are summaries of recent Fred Hutchinson Cancer Research Center research findings and other news. If you’re covering the American Association of Cancer Research’s annual meeting, April 8-13, see our list of Fred Hutch highlights for AACR and contact [email protected] for help setting up interviews with experts.
Most immunocompromised people with a blood cancer called multiple myeloma benefited from a third dose of COVID-19 vaccines, a promising sign after it was shown that two doses tended to not be sufficient for them. However, some people with multiple myeloma still remained vulnerable and may need a fourth dose or antibody treatments as restrictions lift and new variants emerge, according to a fast-tracked study in Cancer Cell.
Showing results
1–50 of 2039
RSS Feeds by Section